Obsidian Therapeutics (NASDAQ:OBX) Short Interest Up ∞ in August

Obsidian Therapeutics (NASDAQ:OBX) saw a significant increase in short interest in the month of August. As of August 14th, there was short interest totaling 36,102 shares, an increase of ∞ from the July 30th total of 0 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average daily trading volume, of 46,658 shares, the short-interest ratio is presently 0.8 days.

Obsidian Therapeutics Trading Down 4.3%

Shares of OBX traded down $0.74 during trading hours on Friday, reaching $16.30. The company had a trading volume of 260,517 shares, compared to its average volume of 147,156. Obsidian Therapeutics has a 12-month low of $14.57 and a 12-month high of $49.97.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Lifesci Capital assumed coverage on shares of Obsidian Therapeutics in a report on Tuesday, August 18th. They issued an “outperform” rating and a $43.00 target price on the stock. Piper Sandler assumed coverage on Obsidian Therapeutics in a research report on Wednesday, August 5th. They issued an “overweight” rating and a $42.00 price target on the stock. Zacks Research upgraded Obsidian Therapeutics to a “hold” rating in a research note on Thursday, August 6th. Finally, TD Cowen initiated coverage on Obsidian Therapeutics in a report on Thursday, August 6th. They set a “buy” rating for the company. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.50.

Obsidian Therapeutics Company Profile

Obsidian Therapeutics is a biotechnology company focused on developing engineered cell and gene therapies for cancer and other serious diseases. The company’s approach is designed to improve the safety, control and effectiveness of therapeutic proteins and genetic medicines by enabling their activity to be regulated inside the body.

Obsidian’s technology platform, known as cytoDRiVE, uses small-molecule-controlled genetic systems to modulate the expression or activity of therapeutic proteins.